Thomas/Wyden Medicare Rx Plan Has Royalty On Federally Funded Research
Executive Summary
Pharmaceutical companies would be required to pay a "return on investment fee" from profits on drugs that benefited from federal research funding under a Medicare drug benefit proposal outlined May 26 by Rep. Thomas (R-Calif.) and Sen. Wyden (D-Ore.).
You may also be interested in...
DTC Restrictions Under Consideration For House Medicare Rx Bill
House Ways & Means Committee leadership is considering adding direct-to-consumer advertising restrictions to Medicare prescription drug benefit legislation.
DTC Restrictions Under Consideration For House Medicare Rx Bill
House Ways & Means Committee leadership is considering adding direct-to-consumer advertising restrictions to Medicare prescription drug benefit legislation.
NIH Royalty Plan Due March 31 Under Wyden Amendment To Funding Bill
The National Institutes of Health would be directed to develop a plan to ensure a "reasonable rate of return" on taxpayer funded research under an amendment to the Senate Labor/HHS appropriations bill.